Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma

ErbB3 has been widely implicated in treatment resistance, but its role as a primary treatment target is less clear. Canonically ErbB3 requires EGFR or ErbB2 for activation, whereas these two established treatment targets are thought to signal independently of ErbB3. In this study, we show that ErbB3...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cell Death Dis
Главные авторы: Redlich, Nathan, Robinson, Anthony M., Nickel, Kwangok P., Stein, Andrew P., Wheeler, Deric L., Adkins, Douglas R., Uppaluri, Ravindra, Kimple, Randall J., Van Tine, Brian A., Michel, Loren S.
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5849045/
https://ncbi.nlm.nih.gov/pubmed/29305574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0029-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы